secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041287
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q2 net loss $34.2M; terminates MDS/AML programs, delays ALTA-002 IND
--------------------------------------------------------------------------------

- GAAP net loss $34.2M ($0.84/share); non-GAAP net loss $27.9M vs $27.1M prior year.
- Cash $224.5M; funding expected through mid-2025 plus $40M term loan availability.
- Terminating ASPEN-02 (MDS) and ASPEN-05 (AML); evorpacept+azacitidine did not improve outcomes.
- ASPEN-06 (gastric cancer) on track for Q4 2023 data update; EU orphan drug designation received.
- ALTA-002 IND delayed to Q1 2024 due to CMC issues; ADC platform expansion deferred.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/0000950170-23-041287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023041287/alxo-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer